Our Company Strategy & Mission Leadership Our Board Partnering Opportunities Out-Licensing Opportunities Contact Our Pipeline Clinical Trials Disease Information Innovation Engine Akeso Partnership Overview Ivonescimab (SMT112) Overview Therapeutic Areas News Center Media Resources Press Releases Investor Center Investor Center Announcements, Financial Reports & Filings Email Alerts Share Price Data Analyst Coverage Corporate Governance Board of Directors Diversity Matrix Shareholder Meetings Summit Presentations Career Opportunities
Efficacy Of SMT19969 And SMT21829 In A Hamster Model Of Clostridium Difficile Associated Disease (CDAD) Efficacy Of SMT19969 And SMT21829 In A Hamster Model Of Clostridium Difficile Associated Disease (CDAD) September 10, 2011 By CKD Digital
Efficacy Of SMT19969 And SMT21829 In A Hamster Model Of Clostridium Difficile Associated Disease (CDAD)
Efficacy Of SMT19969 And SMT21829 In A Hamster Model Of Clostridium Difficile Associated Disease (CDAD) September 10, 2011 By CKD Digital
Website Cookies This website uses cookies: Please see our Privacy Policy to understand how we use cookies. Okay, thanks
